Enabling this transition requires regulatory systems that evolve alongside national ambition.
Over the past few years, India has begun demonstrating precisely that shift. A series of pragmatic reforms in the pharmaceutical regulatory framework signals a broader policy recognition that effective regulation becomes enabling infrastructure for growth, innovation and public health.
At the same time, regulators carry a complex responsibility of balancing innovation, patient safety and access at national scale. As the pharmaceutical sector grows in scientific depth and global reach, that balancing act becomes even more critical.
At the centre of this transition is the Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare. Through targeted policy measures, the regulator has begun aligning oversight more closely with risk and outcomes, maintaining rigour where patient safety demands it while simplifying processes where procedural requirements add limited public health value.
This is not deregulation — it is regulatory maturity.
Process density to policy precision
Highly regulated industries depend on clear rules, predictable timelines and consistent oversight. Yet, over time, regulatory systems can accumulate layers of procedure that outlive their original purpose. When that happens, compliance risks becoming process-heavy without necessarily improving safety outcomes.
The current reform trajectory reflects a shift towards policy precision. The government has adopted calibrated simplification, removing friction where risks are low while strengthening attention where oversight is critical.
This distinction matters because in globally competitive sectors delay is rarely neutral. It redistributes opportunity.
A risk-based framework allows regulators to deploy attention where it matters most, while providing industry with the predictability required for long-cycle investments in research, manufacturing infrastructure and skilled talent.
Enabling research without compromising accountability
One of the most consequential reforms has been the rationalisation of the test licence framework governing research and development (R&D).
Historically, even small-scale non-commercial R&D manufacturing required prior regulatory approvals, often extending experimentation timelines unnecessarily. Recognising that early-stage research carries fundamentally different risk profiles from commercial manufacturing, the regulator has introduced mechanisms that allow companies to proceed through notification rather than prior permission in defined cases.
The change is subtle but significant. It reduces avoidable delays while retaining traceability and regulatory accountability.
For companies investing in scientific discovery, the concern is rarely regulation itself — it is unpredictability. Clear, proportionate frameworks provide confidence to invest in long-cycle research programmes — something India increasingly seeks to attract.
Strengthening export competitiveness
A similar philosophy underpins the simplification of procedures for certain bioavailability and bioequivalence (BA/BE) studies, particularly those undertaken for export markets.
These studies are globally standardised components of generic drug development. Aligning regulatory oversight with their actual risk profile enables faster execution without diluting scrutiny.
For India, one of the world’s most important suppliers of affordable medicines, such efficiencies translate directly into stronger export competitiveness and responsiveness to global demand.
They also allow regulators to focus their resources where scrutiny is genuinely required, improving the overall effectiveness of the regulatory system.
Digitalisation as a structural enabler
Equally important has been the continued expansion of digital regulatory platforms such as SUGAM and the National Single Window System.
Regulatory reform often falters at the point of execution, where policy intent meets administrative complexity.
Digitalisation helps close that gap. Digital workflows improve transparency, reduce discretion and introduce clearer timelines for regulatory processes. For investors and innovators alike, predictable systems reduce risk and strengthen confidence in long-term commitments.
Smart regulation signals confidence
Taken together, these developments reflect a confident regulatory philosophy, one that distinguishes between oversight and overregulation.
A system that focuses on outcomes rather than paperwork, differentiates risk intelligently and aligns with international practices is not weaker. It is more effective.
For global investors, researchers and manufacturers, the signal is clear: India intends to remain both a trusted supplier of medicines and an increasingly attractive destination for pharmaceutical innovation and development.
No regulatory system is ever complete. Continued harmonisation with global standards, consistent implementation across jurisdictions and sustained capacity-building within regulatory institutions will remain important priorities.
Yet the direction of travel is unmistakable. As India positions itself for the next phase of pharmaceutical leadership, regulation will play a decisive role, not as a constraint but as an enabling platform for responsible growth.
When regulation evolves alongside industry ambition, it does more than facilitate compliance — it strengthens national competitiveness.
For India’s pharmaceutical sector, that alignment may prove to be one of the most important drivers of the decade ahead.
The writer is chairman and managing director of Glenmark Pharmaceuticals Ltd
 "pharmaceutical sector, pharma")